跳至主要内容
临床试验/NCT06224062
NCT06224062招募中不适用

Comparison of SARS-CoV-2, AdenoVIRus and Rhinovirus Infection of the Respiratory Epithelium in CHILdren vs. the eLDerly

University Hospital, Bordeaux2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年10月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
2
主要终点
number of viral particles - Adenovirus - Children -24

研究概览

简要总结

The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations.

The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.

详细描述

The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology able to explain differences in the response to respiratory viruses. Several epidemiological and cell-based data have demonstrated that respiratory virus infections differentially affect children, adults or the elderly populations. Perhaps, this difference has been put most notably into the spotlight by the current worldwide pandemic of SARS-CoV-2 with a large part of the deaths occurring in the elderly population whereas very few deaths amongst children have been recorded. According to some studies, this could be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. What is less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium such as rhinovirus and adenovirus cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determines virus susceptibility and virus propagation. Such hypothesis is supported by the literature and our own strong preliminary data. A highly complementing consortium composed of experts in lung physiology, pulmonary transcriptomic, respiratory viruses and ultrastructure analysis will address the question. The investigators will use three major respiratory pathogens (AdV, RV and SARS-CoV-2) to infect reconstituted fully functional respiratory epithelium obtained from children, adults and elderly and study parameters of virus infection and epithelial response. This project should highlight specific therapeutic targets against respiratory viruses with a high prevalence in children such as rhinovirus and adenoviruses to increase the therapeutic arsenal of clinician against those infections.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
— 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • For pediatric patients requiring research-specific bronchial brushing:
  • Child under 18 years old,
  • Requiring bronchoscopy as part of routine care
  • Having informed and signed consent from the holders of parental authority
  • For pediatric patients whose bronchial brushing will be carried out as part of their care and for those whose surgical waste will be collected for research:
  • Child under 18 years old,
  • Requiring as part of routine care bronchoscopy and brushing or bronchial fibroscopy under general anesthesia or surgical resection/lobectomy
  • Having expressed their non-opposition to their child's participation in research
  • For adult patients:
  • Man or woman
  • Aged 18 or over
  • Requiring as part of the care, thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of Haut Lévêque du Chu Hospital in Bordeaux or inclusion in the TUBE study, described below.
  • having received an information note and not having objected to their participation in the research

排除标准

  • No affiliation or non-beneficiary of a social security system
  • During a period of relative exclusion compared to another protocol
  • Patient born before 36 weeks of amenorrhea
  • Patient with a documented history of pulmonary fibrosis, primary pulmonary hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV).
  • Patient with any dental, nasopharyngeal or bronchial infection with fever (> 38°C) requiring systemic antibiotics in the previous 4 weeks

结局指标

主要结局

number of viral particles - Adenovirus - Children -24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children

number of viral particles - Rhinovirus - Children -24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children

number of viral particles - Adenovirus - Adults-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults

number of viral particles - SARS-CoV-2 - Adults-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults

number of viral particles - SARS-CoV-2 - Children-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children

number of viral particles - Rhinovirus - Adults-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults

number of viral particles - Rhinovirus - elderly-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people

number of viral particles - Adenovirus - Elderly-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.

number of viral particles - SARS-CoV-2 - Elderly-24

时间窗: after 24 hours of infection

number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.

次要结局

  • number of viral particles - Rhinovirus - Children-48(after 48 hours of infection)
  • number of viral particles - Rhinovirus - Children-72(after 72 hours of infection)
  • number of viral particles - Rhinovirus - Children-96(after 96 hours of infection)
  • number of viral particles - Rhinovirus - Children-168(after 168 hours of infection)
  • number of viral particles - Adenovirus - Children -48(after 48 hours of infection)
  • number of viral particles - Adenovirus - Children -72(after 72 hours of infection)
  • number of viral particles - SARS-CoV-2 - Children-96(after 96 hours of infection)
  • number of viral particles - SARS-CoV-2 - Children-168(after 168 hours of infection)
  • number of viral particles - Rhinovirus - Adults-48(after 48 hours of infection)
  • number of viral particles - Rhinovirus - Adults-168(after 168 hours of infection)
  • number of viral particles - SARS-CoV-2 - Adults-96(after 96 hours of infection)
  • number of viral particles - Adenovirus - Children -96(after 96 hours of infection)
  • number of viral particles - Adenovirus - Children -168(after 168 hours of infection)
  • number of viral particles - SARS-CoV-2 - Children-72(after 72 hours of infection)
  • number of viral particles - SARS-CoV-2 - Children-48(after 48 hours of infection)
  • number of viral particles - Adenovirus - Adults-48(after 48 hours of infection)
  • number of viral particles - Adenovirus - Adults-72(after 72 hours of infection)
  • number of viral particles - Adenovirus - Adults-96(after 96 hours of infection)
  • number of viral particles - Adenovirus - Adults-168(after 168 hours of infection)
  • number of viral particles - Rhinovirus - Adults-72(after 72 hours of infection)
  • number of viral particles - Rhinovirus - Adults-96(after 96 hours of infection)
  • number of viral particles - Rhinovirus - elderly-48(after 48 hours of infection)
  • number of viral particles - Rhinovirus - elderly-96(after 96 hours of infection)
  • number of viral particles - Adenovirus - Elderly-72(after 72 hours of infection)
  • number of viral particles - Adenovirus - Elderly-96(after 96 hours of infection)
  • number of viral particles - SARS-CoV-2 - Elderly-48(after 48 hours of infection)
  • number of viral particles - SARS-CoV-2 - Elderly-168(after 168 hours of infection)
  • number of viral particles - SARS-CoV-2 - Adults-48(after 48 hours of infection)
  • number of viral particles - SARS-CoV-2 - Adults-72(after 72 hours of infection)
  • number of viral particles - SARS-CoV-2 - Adults-168(after 168 hours of infection)
  • number of viral particles - Rhinovirus - elderly-72(after 72 hours of infection)
  • number of viral particles - Rhinovirus - elderly-168(after 168 hours of infection)
  • number of viral particles - Adenovirus - Elderly-48(after 48 hours of infection)
  • number of viral particles - Adenovirus - Elderly-168(after 168 hours of infection)
  • number of viral particles - SARS-CoV-2 - Elderly-72(after 72 hours of infection)
  • number of viral particles - SARS-CoV-2 - Elderly-96(after 96 hours of infection)

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验